UK markets open in 2 hours 4 minutes

Roche Holding AG (ROG.SW)

Swiss - Swiss Delayed price. Currency in CHF
Add to watchlist
359.65+2.15 (+0.60%)
At close: 05:31PM CET
Sign in to post a message.
  • H
    Henry
    Roche should combine AIVR's drug (a RNA polymerase inhibitor) with a protease inhibitor (PFE's drug). Maybe the combination will be a cure! It should be much better than individual drug.
  • J
    Jane
    Investors in Swiss companies may find GTX, Garrett Motion, Inc., to be of interest. With 222 institutions
    holding, a P.E. of 3.23 and earnings per share of 2.23, this $7.19 stock is held by value investors Oatree Capital
    Management (Howard Marks) and Baupost Group (Seth Klarman), per Yahoo. Both own over 5% of the
    company and the GTX holdings of both are over $28 million. This should be a good long-term holding.
  • F
    Franky
    RHHBY-One of a few stocks up today.
  • B
    Barale
    The latest news about Ronapreve CT’s results should finally push this stock higher!
  • A
    Andi Musaj
    One analyst is now noting that BTC has been holding above a key macro level throughout the past few months. He believes that the recent consolidation above this level bodes well for its near-term outlook and could indicate that significantly further upside is imminent in the weeks and months
    ahead.
  • B
    Bux
    FDA APPROVED - Roche test kits
  • H
    H
    Roche Holding AG said on Monday it has received the U.S. Food and Drug Administr...
    Roche Holding AG said on Monday it has received the U.S. Food and Drug Administr...
    www.reuters.com
  • B
    Bill
    You should buy ACIU (AC IMMUNE) if you want Alzheimer drug exposure, with among the best risk/rewards I have ever seen. ACIU has the broadest portfolio of development stage Azlheimer's drugs with top partners such as Biogen, Eli Lilly, Roche and AbbVie. ACIU has the potential to earn $15 bil in revenues from royalties and payments The market cap of the company is only $400 mil, with $316 mil of net cash, resulting of an enterprise value of only $87 mil. If even one of ACIU's drugs go into commercial production, the stock could go up 10x or more, with limited near-term downside due to the company's strong cash position. ACIU has several drugs in its development pipeline in both stage 1 and stage 2 development, so investors have many shots at goal. There is a huge catalyst coming up on Nov 7th when the company will host a conference on the progress of their drug candidates. Investors have not started paying attention yet, but I think that will happen shortly. I have attached a recent positive recommendation on the stock from Value Investors, which is among the most reputable investors club. https://www.valueinvestorsclub.com/idea/AC_IMMUNE_SA/9888338509
  • c
    choo
    Ark Invest has begun purchasing RHHBY in their ARKG fund. I believe it's due to Roche's heavy investment in individualized cancer immunotherapy. Roche plans to deliver individualized blood testing on individuals with cancer to determine their cancer's genetic profile. The cancers genetic profile will then be used to individualize cancer therapies to the patients. Also, according to Morningstar, Roche is a wide moat stock that is very undervalued (five stars). Long!!!!!
  • A
    AJ
    Roche (OTCQX:RHHBY) unit, Genentech announces that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the FDA, in combination with Tecentriq (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC).
    Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.
  • T
    TOM
    To clarify further on the two analyzers from Roche, the newest one can analyze over 4000 cases in 24 hours and have the results within four hours. There are quite a large number of analyzers in the United States and in the rest of the world. Now a patient can get their results within a few hours, not days or weeks which is important to the growth  statistics to determine what’s happening in our country in any locale.
  • A
    Andy
    This company would have to cure cancer for it to move up significantly. Good news almost every week and ARK buying thousands of shares and it goes down or barely moves up.
  • S
    Scott
    Roche approaching another new high... Slowly but surely creating wealth for shareholders. Best in class biotech and diagnostics play IMO.
  • D
    Donald
    We hear so much about the test kits and that is fine. But, the great news that we don't hear much about is Roche's drug Actemra which blocks the function of interleukin-6 causing inflammation in the lungs for those infected with the Corona virus. It was used with success to keep people off ventilators in China who did well. All 21 people in their trial did well. It was also used with success in Italy. The results were impressive so says Regeneron who has a similar drug called Kevzara. They have started a trial with their drug which could be ready in abundance by summer. So, Regeneron stock is soaring . Roche stock should be soaring as well.
  • b
    bpowers
    Okay, now that it's approved the US Government should put it to good use. The Red Cross is clearly in need of blood during this pandemic and the Roche test requires a blood draw. The government should provide these tests to the Red Cross so that they can encourage Americans to come in, give blood and get a free anti body test for their efforts. I'm sure they are many people who don't want to go into a standard lab right now. I suspect that there are just as many who don't want to give blood. But if one can give blood in a Covid free environment and get antibody test in the process then it sounds like a win win for everyone.
  • w
    wooglin
    My RHBBY div was credited to my brokerage AC on Monday.
    1.0746/share
    Unlike in the past, the foreign withholding was MUCH greater; the net (including 0.02/sh ADR fee) amount I received was .67849/share
    1.0746 - 0.37611 (taxes) - 0.02 = .67849

    In the previous three years I've had a position, 15% of the gross dividend was withheld for foreign taxes, but this year 35% was withheld.

    Comments from those more schooled in this?
    Cheers.
  • A
    Andy
    Nothing seems to move this stock. News of an FDA approval and it goes down.
  • D
    Dee
    This is a gold mine. They are supplying test kits to the US, WHO, and other countries. Apply the law of supply and demand, test kit price goes up when demand is increase. I can't imagine the revenue they are going make by selling this kit.

    https://www.roche.com/dam/jcr:7a1981f0-3b90-434e-b026-3c1a41194e09/en/200304_Update_Statement_roche.pdf
  • S
    Scott
    Roche expected to acquire ONCE (Spark Therapeutics) for $5B, which is a significant premium over current $2B valuation. Curious was Roche holders think about the potential deal.
  • M
    Mark
    There is a rumor coming from one of the biggest consultings in the world which states that "The Pharmatheutical Swiss company Roche is about to announce the launching of a takeover bid over the little Spanish Biotecnological company Pharmamar S.A.The takeover bid amounts to 159#$%$ per share, with a total operation of 2950 millions euros and it would be launched within the second half of september.The Spanish company actually has three marine based drugs in the market to treat oncologic diseases as well as a large portofolio composed by 1500 patents and 180.000 molecules that could supply all Roche companies and affialiates to begin investigations for all kind of diseases.Pharmamar also has a promising drug under study "Plitidepsin" which as the company states it could be the most powerful antiviral ever discovered, which has attract several Pharmatheutics like Roche.Since the acquisition of Genentech, Roche's politics have been to make bigger, buying small and medium Biotecnologic companies such as Seragon, InterMune, Ignyta, Genia, Jecure, Illumina, Spar Therapeutics, Trophos, Santarias Pharma or Foundation Medecine.According to these sources, several Founds that have invested in the Spanish Comoany during the last years, would accept the takeover bid to sell their shares and collect capital gains due to a possible upcoming potential worldwide crisis in other sectors of their investments.These Founds would have a minimum of 16% of participation, the 22% of Steakholders belongs to the company management group and then there would be a free float of around 60%.Big Found as Vanguards, Blackrock, Norges Bank, Dimensional Fund, Findel, Schroder Investment or Northern Trust are already positioned in the company Pharmamar S.A